Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04221061 · ClinicalTrials.gov registry record · Early Phase 1
18F-FluorThanatrace (PET/CT) in Glioblastoma
A Early Phase 1 study, sponsored by University of Pennsylvania.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 3
- Enrollment target
NCT04221061: Clinical Trial Early Phase 1 study, sponsored by University of Pennsylvania.
NCT04221061 is a Early Phase 1 study that was terminated before completion, run by University of Pennsylvania. The registered enrollment target is 3 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04221061, a Early Phase 1 study, was terminated before completion, sponsored by University of Pennsylvania.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The subject will be a candidate for this imaging study because they have agreed to participate in a treatment study involving TTFields (Optune device), a device that uses low intensity, wave like electrical fields, and a PARP inhibitor drug (niraparib). The research study is being conducted to test how a new radioactive imaging drug called 18F-Fluorthanatrace (18F-FTT) can be used to image sites of recurrent brain cancer before or after new treatment or surgery. 18F-FTT is a drug used with an imaging test called Positron Emission Tomography/Computed Tomography (PET/CT).
Primary Outcome
Evaluate uptake of \[18F\]FTT in recurrent glioblastoma after initiation of TTFields therapy.
Interventions
- DRUG 18F-FluorThanatrace
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2020-02-20 |
| Est. Completion | 2024-06-10 |
| Phase | Early Phase 1 |
Why NCT04221061 stopped before completion
NCT04221061 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 1 intervention - of which 18F-FluorThanatrace is the first listed.
NCT04221061 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04221061 about?
NCT04221061 is a clinical study titled "18F-FluorThanatrace (PET/CT) in Glioblastoma". The subject will be a candidate for this imaging study because they have agreed to participate in a treatment study involving TTFields (Optune device), a device that uses low intensity, wave like electrical fields, and a PARP inhibitor drug (niraparib). The research study is being conducted to test ...
What is the current status of trial NCT04221061?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 3 participants. The study started on 2020-02-20. Estimated completion is 2024-06-10.
What interventions are being tested in trial NCT04221061?
The interventions under investigation include: 18F-FluorThanatrace (DRUG).
Who is sponsoring clinical trial NCT04221061?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04221061's enrollment target sits among peer trials
3 1948th of 2000 higher than 28 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI